Updates are available Correction dated 2022-11-23
Click to view Correction: https://doi.org/10.1038/s41541-022-00578-7
-
Authors
Voigt, Emily A. http://orcid.org/0000-0001-5177-4063
Gerhardt, Alana
Hanson, Derek
Jennewein, Madeleine F. http://orcid.org/0000-0001-6633-7413
Battisti, Peter
Reed, Sierra
Singh, Jasneet
Mohamath, Raodoh
Bakken, Julie
Beaver, Samuel
Press, Christopher
Soon-Shiong, Patrick
Paddon, Christopher J. http://orcid.org/0000-0003-4182-2855
Fox, Christopher B.
Casper, Corey
-
Funding
Funding for this research was provided by:
Amyris, Inc., and ImmunityBio, Inc.
- License Information
-
More Information
Article History
Received: 25 March 2022
Accepted: 6 October 2022
First Online: 2 November 2022
Change Date: 23 November 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41541-022-00578-7
Competing interests
: A.G., C.B.F., C.J.P., E.A.V., and P.S.S. declare no competing non-financial interests but the following competing financial interests. C.B.F. is co-inventor on patent applications relating to PCT/US2018/37783, “Nanostructured Lipid Carriers and stable emulsions and uses thereof.” A.G. and E.A.V. are co-inventors on U.S. patent application nos. PCT/US21/40388, “Co-lyophilized RNA and Nanostructured Lipid Carrier,” and 63/144,169, “A thermostable, flexible RNA vaccine delivery platform for pandemic response.” C.J.P. owns shares and possesses stock options in Amyris, Inc. P.S.S. owns shares of ImmunityBio, Inc. All other authors declare they have no competing interests.
